Dysport News and Research

RSS

New report reveals costs related to surgical and minimally-invasive cosmetic procedures

A new report from the American Society of Plastic Surgeons (ASPS) reveals that Americans spent more than ever before - $16 billion - on cosmetic plastic surgery and minimally-invasive procedures in 2016.

12 Apr 2017

Special review highlights benefits of using botulinum neurotoxin for treating facial wrinkles

Botox and other botulinum neurotoxin (BoNT) products are widely known for their use in treating facial wrinkles--but they can also be used to treat a wide range of non-cosmetic problems.

31 Aug 2016

New Botox-like treatment can help runners, cyclists with knee pain

A painful knee condition that affects more than one in eight active people has been treated effectively with a botulinum toxin injection and physiotherapy.

24 Feb 2016

Dysport phase III study results in children with cerebral palsy with lower limb spasticity published in Pediatrics

Ipsen today announced that the scientific journal Pediatrics published the detailed results of the phase III randomized study showing both the efficacy and the safety of Dysport in the treatment of dynamic equinus foot deformity, a condition associated with cerebral palsy in children.

28 Jan 2016

FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

Allergan plc, a leading global pharmaceutical company today announced that the U.S. Food and Drug Administration has accepted the company's resubmission of its Supplemental Biologics License Application (sBLA) for BOTOX (onabotulinumtoxinA) for the treatment of adults with lower limb (involving ankle and toe muscles) spasticity in adults.

20 Aug 2015

Galderma obtains FDA approval for Restylane Lyft to restore structure to the cheeks and midface area

Galderma, a global healthcare company focused on skin health, announced today that it has received U.S. Food and Drug Administration approval to market Restylane Lyft for cheek augmentation and the correction of age-related midface contour deficiencies in patients over the age of 21.

2 Jul 2015

3-D imaging technique may be useful for measuring efficacy of injectable wrinkle reducers

A three-dimensional imaging technique often used in the automotive and aerospace industries for accurate measurement may be useful to measure the efficacy of injectable wrinkle reducers such as Botox and Dysport, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

28 May 2015

Dermatology expert to deliver presentation at 2015 ODAC

A leader in the specialty of cosmetic dermatology, Dr. Leslie Baumann of Miami, Florida will be a featured speaker at the Orlando Dermatology Aesthetic & Clinical Conference (ODAC) in Orlando January 16-19, 2015.

1 Dec 2014

Ipsen Biopharmaceuticals implements enhanced patient support program

Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen today announced the implementation of IPSEN CARESTM (Coverage, Access, Reimbursement, & Education Support).

25 Nov 2014

Cedars-Sinai experts to present free conference on dystonia for patients, families and caregivers

A multidisciplinary team of experts affiliated with the Cedars-Sinai Movement Disorders Program will present a free conference for patients, families and caregivers on treatment options for dystonia, which causes painful and potentially crippling muscle contractions.

30 Sep 2014

Ipsen: Dysport Phase IIa clinical trial effective in treatment of NDO

Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) today announced positive results from its phase IIa clinical trial assessing Dysport in the treatment of Neurogenic Detrusor Overactivity (NDO) in patients with urinary incontinence not adequately managed by anticholinergics.

19 Mar 2014

Aradigm reports record revenue of $4.6M in fourth quarter 2013

Aradigm Corporation (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2013.

13 Mar 2014

Ipsen reports positive initial results from Dysport phase III study in Adult Upper Limb spasticity

Ipsen today announced positive initial results from the double-blind phase III study of Dysport (abobotulinumtoxinA) in Adult Upper Limb spasticity. Regarding the primary endpoints, treatment with Dysport showed statistically significant response versus placebo in the improvement of muscle tone, as measured by the Modified Ashworth Scale.

17 Dec 2013

Ipsen, Harvard initiate collaboration to discover, develop botulinum toxins for neurologic diseases

Ipsen announced today that it has initiated a research and development collaboration on novel engineered botulinum toxins with Harvard Medical School.

15 Jul 2013

FDA approves Allergan’s BOTOX to treat overactive bladder

Allergan, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BOTOX (onabotulinumtoxinA) for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency in adults who have had an inadequate response to or are intolerant of an anticholinergic medication.

19 Jan 2013

Ipsen, Active Biotech complete enrollment in tasquinimod Phase III trial for prostate cancer

Active Biotech and Ipsen today announced that the Phase III clinical trial for tasquinimod, a novel compound for the treatment of prostate cancer, is successfully enrolled with over 1,200 randomized patients as planned in the clinical protocol.

10 Dec 2012

Inspiration, Ipsen receive FDA Fast Track designation for OBI-1 to treat AHA

Ipsen and Inspiration Biopharmaceuticals Inc. today announced that Inspiration has received Fast Track designation from the US Food and Drug Administration (FDA) for OBI-1 in acquired hemophilia A.

20 Nov 2012

Gateway Aesthetic announces addition of three new procedures

The Gateway Aesthetic Institute & Laser Center in Salt Lake City, Utah is pleased to announce the addition of three new procedures to its broad list of available services in the aesthetics' arena.

5 Nov 2012

Active Biotech, Ipsen announce new data on biomarkers from tasquinimod Phase II study in CRPC

Active Biotech and Ipsen have presented a new set of data on biomarkers from the previously concluded tasquinimod Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer (CRPC) at the scientific congress ESMO (European Society for Medical Oncology) held in Vienna September 28-October 2.

1 Oct 2012

Inspiration receives FDA clinical hold order for IB1001 phase III studies on hemophilia B

Ipsen announced today that its partner Inspiration Biopharmaceuticals Inc. (Inspiration) was notified by the Food and Drug Administration (FDA) that both clinical trials evaluating the safety and efficacy of IB1001, an investigational intravenous recombinant factor IX (rFIX) therapy for the treatment and prevention of bleeding episodes in people with hemophilia B, were placed on clinical hold.

10 Jul 2012